학술논문
Case Reports of Pre-clinical Replication Studies in Metabolism and Diabetes.
Document Type
Academic Journal
Author
von Herrath M; Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA. Electronic address: mtvh@novonordisk.com.; Pagni PP; Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.; Grove K; Novo Nordisk Research Center Seattle, Inc., Seattle, WA, USA.; Christoffersson G; Department of Medical Cell Biology, Uppsala University, Uppsala, Sweden.; Tang-Christensen M; Novo Nordisk A/S, Måløv, Denmark.; Karlsen AE; Novo Nordisk A/S, Måløv, Denmark.; Petersen JS; Novo Nordisk A/S, Måløv, Denmark.
Source
Publisher: Cell Press Country of Publication: United States NLM ID: 101233170 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1932-7420 (Electronic) Linking ISSN: 15504131 NLM ISO Abbreviation: Cell Metab Subsets: MEDLINE
Subject
Language
English
Abstract
Recent articles have highlighted the lack of reproducibility of data from scientific publications. Here we would argue that a better way to describe and also tackle this matter is to use the term "lack of robustness," since it points toward potential solutions. Presenting several case reports, we highlight examples with common underlying issues from Novo Nordisk's experience: animal model variability, reagent quality, and inter-lab variability. We discuss means to prevent these issues and argue for increased collaborative work and transparent manuscript revision procedures. Collectively, we believe these measures will help promote a more rapid and efficient self-corrective process in diabetes drug target research.
(Copyright © 2019 Elsevier Inc. All rights reserved.)
(Copyright © 2019 Elsevier Inc. All rights reserved.)